Search - tctmd.com

Displaying 861 - 880 of 2992

Sort: Relevancy | Date

News Conference News TCT 2018

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

TCT Daily Staff

September 28, 2018

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

L.A. McKeown

September 27, 2018

News Conference News TCT 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Shelley Wood

September 26, 2018

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Todd Neale

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News TCT 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

Yael L. Maxwell

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2018

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

Presenter: James B. Hermiller Jr, Hiroki Shiomi

September 25, 2018

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

Presentation TCT 2018

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Presenter: Felix Mahfoud, Patrick W. Serruys, Pieter C. Smits

September 25, 2018

Presentation TCT 2018

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

Presenter: Felix Mahfoud, Patrick W. Serruys, Gregg W. Stone

September 25, 2018

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Todd Neale

September 25, 2018

News Opinion Off Script TCT 2018

Off Script: Opacity, Transparency, and Magic Buttons in the Cath Lab

Kwan S. Lee

September 24, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2018

The Watch TAVR Trial: Rationale, Design and Status

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Samir R. Kapadia

September 24, 2018

News Conference News TCT 2018

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

Lucy Hicks

September 24, 2018

Presentation TCT 2018

Is Multivessel Revascularization During Primary PCI in STEMI Necessary, Desirable, or Contraindicated?

Presenter: Michael Kang-Yin Lee, Ivo Petrov, Marin Postu, Zoltan Ruzsa, Stefan Mot

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

Case #8: Severe Obstructive HCM in a Symptomatic Patient Despite Maximized Medical Therapy and Septal Thickness of 13 mm.

Presenter: Sherif F. Nagueh, Hubert Seggewiss, John S. Douglas Jr, Valerian Fernandes, Vijay Iyer, Srihari S. Naidu, Nish Patel, Alexandre C. Zago

September 24, 2018

Presentation TCT 2018

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

Presenter: Zahid Amin, Robert J. Sommer, Peter C. Block, John P. Breinholt, Craig E Fleishman, Jan Kovac, Harsimran Sachdeva Singh, Christian Spies

September 24, 2018

Advertisement

Prosthetic Valve Endocarditis Rate Similarly Low for TAVR vs SAVR

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Off Script: Opacity, Transparency, and Magic Buttons in the Cath Lab

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

The Watch TAVR Trial: Rationale, Design and Status

ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year

Is Multivessel Revascularization During Primary PCI in STEMI Necessary, Desirable, or Contraindicated?

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Case #8: Severe Obstructive HCM in a Symptomatic Patient Despite Maximized Medical Therapy and Septal Thickness of 13 mm.

A Patient With Atrial Fibrillation, Cryptogenic Stroke, and PFO: Watchman Despite OAC?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content